As of June 2, 2025, AstraZeneca PLC (AZN.L) reports a EV/EBITDA of 14.06.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing AstraZeneca PLC's EV/EBITDA to Peers
To better understand AstraZeneca PLC's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| AstraZeneca PLC (AZN.L) | 14.06 |
| Karo Pharma AB (KARO.ST) | 305.92 |
| Dechra Pharmaceuticals PLC (DPH.L) | 32.10 |
| Financiere de Tubize SA (TUB.BR) | 30.72 |
| ALK-Abello A/S (ALK B.CO) | 26.88 |
| Orion Oyj (ORNBV.HE) | 19.38 |
Compared to its competitors, AstraZeneca PLC's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.